Cargando…

The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis

BACKGROUND: Vascular endothelial growth factor (VEGF) is a key mediator that plays an important role in angiogenesis, tumor growth, and tumor metastasis. The associations between five polymorphisms of VEGF (rs3025039, rs699947, rs10434, rs1570360, and rs2010963) and renal cell carcinoma (RCC) risk h...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiao, Shen, ChangXin, Fu, YouRong, Yu, Tian, Song, JingJing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367456/
https://www.ncbi.nlm.nih.gov/pubmed/28356760
http://dx.doi.org/10.2147/OTT.S125965
_version_ 1782517776046358528
author Wang, Jiao
Shen, ChangXin
Fu, YouRong
Yu, Tian
Song, JingJing
author_facet Wang, Jiao
Shen, ChangXin
Fu, YouRong
Yu, Tian
Song, JingJing
author_sort Wang, Jiao
collection PubMed
description BACKGROUND: Vascular endothelial growth factor (VEGF) is a key mediator that plays an important role in angiogenesis, tumor growth, and tumor metastasis. The associations between five polymorphisms of VEGF (rs3025039, rs699947, rs10434, rs1570360, and rs2010963) and renal cell carcinoma (RCC) risk have been extensively investigated, but the currently available results are inconsistent and inconclusive. To obtain a more accurate assessment of the associations, we conducted a meta-analysis in this study. MATERIALS AND METHODS: Relevant studies were collected systemically from the following three electronic databases: MEDLINE, Web of Science, and CNKI (Chinese National Knowledge Infrastructure). Statistical analyses were performed using Review Manager 5.2 in a fixed- or random-effects model. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to establish the strength of associations. RESULTS: A total of eight case–control studies with 1,936 RCC cases and 2,770 controls fulfilling the inclusion criteria were selected for this meta-analysis. The pooled OR indicated that rs699947 polymorphism was significantly associated with RCC risk in all genetic models. A significant association was also found between the rs3025039 polymorphism and RCC risk in a homozygous model (TT vs CC: OR =1.38, 95% CI =1.11–1.72, P=0.004), a dominant model (CT+TT vs CC: OR =1.21, 95% CI =1.05–1.39, P=0.01), and a recessive model (TT vs CC+CT: OR =1.28, 95% CI =1.04–1.57, P=0.02). After a subgroup analysis of ethnicity in the allele contrast model of rs3025039 polymorphism, we found a significant relationship in the allele contrast model (T vs C: OR =1.21, 95% CI =1.05–1.40, P=0.007) in the Asian population. With regard to rs10434 polymorphism, significant association was observed only in a homozygous model (GG vs AA: OR =0.75, 95% CI =0.57–0.98, P=0.03). As to rs1570360 or rs2010963, we did not observe any relationship between the two polymorphisms and RCC risk in our study. CONCLUSION: Our meta-analysis confirmed the fact that rs699947, rs3025039, and rs10434 polymorphisms were significantly relevant to elevated RCC risk. In the meanwhile, this study also demonstrated that the allele contrast model of rs3025039 polymorphism was likely to be associated with risk of RCC in the Asian population.
format Online
Article
Text
id pubmed-5367456
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53674562017-03-29 The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis Wang, Jiao Shen, ChangXin Fu, YouRong Yu, Tian Song, JingJing Onco Targets Ther Original Research BACKGROUND: Vascular endothelial growth factor (VEGF) is a key mediator that plays an important role in angiogenesis, tumor growth, and tumor metastasis. The associations between five polymorphisms of VEGF (rs3025039, rs699947, rs10434, rs1570360, and rs2010963) and renal cell carcinoma (RCC) risk have been extensively investigated, but the currently available results are inconsistent and inconclusive. To obtain a more accurate assessment of the associations, we conducted a meta-analysis in this study. MATERIALS AND METHODS: Relevant studies were collected systemically from the following three electronic databases: MEDLINE, Web of Science, and CNKI (Chinese National Knowledge Infrastructure). Statistical analyses were performed using Review Manager 5.2 in a fixed- or random-effects model. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to establish the strength of associations. RESULTS: A total of eight case–control studies with 1,936 RCC cases and 2,770 controls fulfilling the inclusion criteria were selected for this meta-analysis. The pooled OR indicated that rs699947 polymorphism was significantly associated with RCC risk in all genetic models. A significant association was also found between the rs3025039 polymorphism and RCC risk in a homozygous model (TT vs CC: OR =1.38, 95% CI =1.11–1.72, P=0.004), a dominant model (CT+TT vs CC: OR =1.21, 95% CI =1.05–1.39, P=0.01), and a recessive model (TT vs CC+CT: OR =1.28, 95% CI =1.04–1.57, P=0.02). After a subgroup analysis of ethnicity in the allele contrast model of rs3025039 polymorphism, we found a significant relationship in the allele contrast model (T vs C: OR =1.21, 95% CI =1.05–1.40, P=0.007) in the Asian population. With regard to rs10434 polymorphism, significant association was observed only in a homozygous model (GG vs AA: OR =0.75, 95% CI =0.57–0.98, P=0.03). As to rs1570360 or rs2010963, we did not observe any relationship between the two polymorphisms and RCC risk in our study. CONCLUSION: Our meta-analysis confirmed the fact that rs699947, rs3025039, and rs10434 polymorphisms were significantly relevant to elevated RCC risk. In the meanwhile, this study also demonstrated that the allele contrast model of rs3025039 polymorphism was likely to be associated with risk of RCC in the Asian population. Dove Medical Press 2017-03-21 /pmc/articles/PMC5367456/ /pubmed/28356760 http://dx.doi.org/10.2147/OTT.S125965 Text en © 2017 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wang, Jiao
Shen, ChangXin
Fu, YouRong
Yu, Tian
Song, JingJing
The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
title The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
title_full The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
title_fullStr The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
title_full_unstemmed The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
title_short The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
title_sort associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367456/
https://www.ncbi.nlm.nih.gov/pubmed/28356760
http://dx.doi.org/10.2147/OTT.S125965
work_keys_str_mv AT wangjiao theassociationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT shenchangxin theassociationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT fuyourong theassociationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT yutian theassociationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT songjingjing theassociationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT wangjiao associationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT shenchangxin associationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT fuyourong associationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT yutian associationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis
AT songjingjing associationsbetweenfivepolymorphismsofvascularendothelialgrowthfactorandrenalcellcarcinomariskanupdatedmetaanalysis